Matinas BioPharma Holdings, Inc. (MTNB) is a publicly traded Healthcare sector company. As of May 21, 2026, MTNB trades at $0.57 with a market cap of $3.46M and a P/E ratio of -0.30. MTNB moved +14.52% today. Year to date, MTNB is -0.64%; over the trailing twelve months it is -16.08%. Its 52-week range spans $0.47 to $4.25. Rallies surfaces MTNB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Matinas Faces Delisting Risk After Reporting $4.83M Equity Against $6M Requirement: Matinas BioPharma reported stockholders’ equity of $4.83 million as of December 31, 2025, and received an April 2 notice that it failed to meet NYSE American’s $6.0 million equity requirement after five years of losses. The company must submit a compliance plan by May 2, 2026, to avoid delisting proceedings.
| Metric | Value |
|---|---|
| Price | $0.57 |
| Market Cap | $3.46M |
| P/E Ratio | -0.30 |
| EPS | $-2.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.25 |
| 52-Week Low | $0.47 |
| Volume | 1.97K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-10.35M |
| Gross Margin | 0.00% |
MTNB analyst coverage data. Average price target: $0.00.